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efficiency, a cellular phone reporting programme was 
also integrated into the system after the earthquake in 
Sichuan province in 2008. Local hospitals report incident 
cases of scarlet fever to the national and provincial 
Centers for Disease Control and Prevention (CDC). 
Additionally, the Chinese Government strengthened 
its overall public health disease surveillance following 
the establishment of the national surveillance system 
with a ten-fold increase in public health funding. The 
surveillance system covers 39 notifiable infectious 
diseases, which are divided into three classes—A, B, and 
C. As a class B infectious disease, scarlet fever incidence 
should be reported to the network within 24 h of 
diagnosis. If a high incidence of scarlet fever was indicated 
in a particular region, the national and local CDC should 
collaborate to take appropriate measures to isolate the 
infected individuals. Moreover, the surveillance system 
would provide a more standardised and comprehensive 
description of scarlet fever, and aggregated data from 
the system would allow further examination of potential 
patient characteristics that are associated with the 
disease,8–10 including long-term patterns, seasonality, 
and spatial features. These data would provide reference 
values to better understand the disease and inform 
public health decision making. Although surveillance 
systems have progressed in the past decade, they can still 
be improved. The current surveillance system in China 
collects several patient sociodemographic characteristics, 
including age, sex, occupation, living address, and the 
hospital to which they reported. However, data on clinical 
characteristics, such as laboratory test results, should also 
be included in the future.
In response to the resurgence of scarlet fever, the 
Chinese Government has taken measures for disease 
control and prevention. Those measures include 
improving diagnosis of the disease, strengthening 
surveillance among school students, and establishing 
an improved and efficient epidemic response to 
scarlet fever outbreaks. Given the establishment of the 
universal two-child policy and the ageing population, 
the distribution of age in China’s population is gradually 
changing.6 The spectrum of infectious diseases could 
also change as a result. Age-related infectious diseases 
like scarlet fever should be better monitored by way of 
national surveillance systems. The surveillance system 
will have a crucial role in the prevention and control of 
infectious disease. 
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Reappraising the cardiosafety of dihydroartemisinin-piperaquine
The arsenal of efficacious drugs for the treatment of 
malaria remains small and is clearly insufficient to tackle 
the global burden of malaria, with more than 216 million 
clinical episodes and nearly half a million deaths 
annually.1 Among the new antimalarials that have been 
developed in the past decade, the artemisinin-based 
combination dihydroartemisinin–piperaquine is one of 
the most promising, on account of its good efficacy and 
tolerability, simplified dose schedule (ie, once daily for 
3 days), and long post-treatment prophylactic effect.2 
The only brand of dihydroartemisinin–piperaquine that 
has been registered under stringent regulatory authority 
is Eurartesim (licensed by the European Medicines 
Agency [EMA] in 2011), although at least three other 
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brands exist: Duo-cotecxin (also prequalified by 
WHO), D-ARTEPP, and Arterakine. Dihydroartemisinin–
piperaquine is not only used as a treatment of 
uncomplicated malaria but also has been proposed 
as an alternative to sulphadoxine–pyrimethamine for 
intermittent preventive treatment of malaria during 
pregnancy,3 or as a suitable drug for the mass treatment 
of entire populations as part of malaria-elimination 
endeavours.4
However, because piperaquine can cause a dose-
dependent effect on cardiac repolarisation, which 
can manifest as a prolonged QT interval in surface 
electrocardiograms (ECG), concerns have been raised 
regarding the cardiosafety of dihydroartemisinin–
piperaquine, which have limited its much wider 
deployment and use. Indeed, such potentially pro-
arrhythmogenic characteristics, which theoretically 
could be linked to an increased risk of ventricular 
fibrillation and sudden death, led the EMA to 
recommend that an ECG should be done before 
the drug’s administration, that the drug should be 
administered under strict fasting conditions (because 
food increases piperaquine’s plasma concentration), 
and that repeated doses should be limited in number 
and frequency.5 These recommendations reduced 
the potential use of the drug in most areas of the 
world where malaria remains highly endemic. 
Dihydroartemisinin–piperaquine has since become one 
of the most studied drugs in relation to its associated 
repolarisation-related cardiotoxicity, conditions that 
were not applied to other antimalarial drugs with similar 
potential (quinine, amodiaquine, or chloroquine) when 
they were licensed, more than half a century ago.
Although the occurrence of clinically relevant 
adverse cardiovascular effects associated with dihydro- 
artemisinin–piperaquine or piperaquine on its own 
after several years of extensive use seems rare, the 
drug’s association with life-threatening cardiac events 
remains unchallenged. In this issue of Lancet Infectious 
Diseases, Xin Hui S Chan and colleagues6 present the 
results of a systematic review and meta-analysis of 
94 studies including nearly 200 000 pooled individuals 
given dihydroartemisinin–piperaquine for several 
indications, including treatment of uncomplicated 
malaria, intermittent preventive treatment, and 
mass drug administration. The investigators com- 
pared the risk of sudden unexplained death after 
dihydro-artemisinin–piperaquine with the baseline rate 
of sudden cardiac death in a reference population aged 
younger than 35 years, chosen to reflect the typical age 
of antimalarial users in malaria-endemic areas.
The median pooled risk estimate of sudden 
unexplained death after dihydroartemisinin–pipe- 
raquine was 1 in 757 950 (95% CI 1 in 2 854 490 to 
1 in 209 114), a finding deemed to be similar (and not 
higher) than the baseline rate of sudden cardiac death 
in the reference population after standardisation to 
30-day risks (0∙7–11∙9 per 100 000 person-years or 
1 in 1 714 280 to 1 in 100 835). The investigators also 
examined the 61 deaths of individuals in the studies 
who received the drug, 31 of which occurred during the 
3-day treatment period, and a further 30 that occurred 
during one terminal elimination half-life of piperaquine 
(around 30 days). Members of a WHO Expert Review 
Group, specifically convened to review the cardiosafety 
of antimalarial drugs,7 concluded that only one of these 
deaths (of a healthy woman aged 16 in Mozambique 
who developed heart palpitations several hours after 
the second dose of dihydroartemisinin–piperaquine and 
collapsed and died on the way to hospital) was consistent 
with sudden cardiac death and possibly causally related 
to drug exposure. Although under-reporting is likely, 
that only one death among nearly 200 000 studied 
individuals could be linked to the drug strongly supports 
the idea that sudden deaths potentially attributable to 
repolarisation-related tachyarrhythmia after treatment 
with dihydroartemisinin–piperaquine are infrequent.
These reassuring data further corroborate the 
conclusions of the aforementioned WHO expert 
panel,7 of findings from a previous smaller systematic 
review and meta-analysis on this subject,3 and of 
various surveillance efforts undertaken by many 
independent research groups to study the safety of 
dihydroartemisinin–piperaquine.2,8–10 Additionally, a 
multicentre clinical trial in five sub-Saharan African 
countries of a new dispersible paediatric formulation 
of dihydroartemisinin–piperaquine in infants aged 
6–12 months did not note any clinical cardiosafety 
concerns.11 Further studies (NCT02605720) assessing 
the safety in healthy individuals (including detailed 
ECG assessment) of cumulative repeated monthly 
treatment with dihydroartemisinin–piperaquine, mi- 
micking regimen used in mass-drug administration are 
underway.
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Reappraising the value of the few available effective 
antimalarials is more important now than ever. The 
global effort against malaria is at a crossroads;12 malaria 
incidence seems to be rising again after many years 
of decreases. Dihydroartemisinin–piperaquine should 
be shed of its cardiotoxic reputation, so that malaria-
endemic areas can benefit from its full potential and to 
decrease the toll that malaria still imposes globally.
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HRP-2 deletion: a hole in the ship of malaria elimination
Malaria remains a major health challenge in tropical 
and subtropical countries with an estimated incidence 
of 216 million cases and 445 000 deaths worldwide in 
2016. Every 2 minutes a child under 5 years old dies 
because of malaria. India accounts for 80% of malaria 
cases and 60% of malaria deaths in the southeast 
Asia region (SEAR).1 Plasmodium falciparum malaria 
constitutes 63∙4 % of total malaria cases in India. More 
than 90% of malaria cases in India are reported from 
remote, difficult to reach rural and tribal areas, where 
the diagnosis of malaria is a challenge in resource-
limited settings.
Malaria rapid diagnostic tests (RDTs) have been 
extensively used as diagnostic tools because of their 
ease of handling and quick results. The sale of about 
1∙66 billion malaria RDTs across the globe during 
2010–16 speaks volumes about their utility.1 Improved 
sensitivity and heat stability makes P falciparum-
histidine rich protein (HRP) 2 based RDTs the preferred 
choice for timely diagnosis of falciparum malaria in 
remote areas with poor health-care infrastructure. 
Berhane and colleagues have shown high prevalence 
(41–80%) of HRP2 gene deletion in P falciparum 
and high frequency of false negative RDT results, 
irrespective of parasite densities, in a hospital-based 
study in Eritrea.2 At a time when India and several other 
countries in SEAR are accelerating the pace of malaria 
control programmes to achieve the goal of malaria 
elimination by 2030, the deletion of HRP2 is a matter of 
serious concern, since RDTs are the mainstay diagnostic 
tool for community surveys, along with microscopy in 
hospitals. The diverse ecological conditions, difficult 
